NCT01497496 2021-04-27
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Dana-Farber Cancer Institute
Genentech, Inc.
University of Sao Paulo